National & International Guidelines on Lipoprotein Apheresis for refractory FH and HyperLp(a)aemia

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "National & International Guidelines on Lipoprotein Apheresis for refractory FH and HyperLp(a)aemia"

Transcription

1 National & International Guidelines on Lipoprotein Apheresis for refractory FH and HyperLp(a)aemia Europe Nordestgaard et al. Lipoprotein (a) as a cardiovascular risk factor. Eur Heart J 2010; 31: Germany Working Party on Medical Treatment of the Federal Committee of Physicians and Health Insurance Companies. Code of Social Law 2003; vol V (SGB V). Italy Stefanutti C. 2nd Italian Consensus Conference on LDL-apheresis. Nutr Metab Cardiovasc Dis 2010; 20: Japan Harada-Shiba et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19: Spain Civiera F for International Panel on Management of Familial Hypercholesterolemia. Atherosclerosis 2004;173: UK Thompson GR, HEART-UK LDL Apheresis Working Group. Atherosclerosis 2008; 198: NICE clinical guideline 71. Identification and management of familial hypercholesterolaemia. August USA Sczepiorkowski et al. Guidelines on the use of therapeutic apheresis in clinical practice - American Society for Apheresis. J Clin Aph 2007; 22: Ito et al. National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S Courtesy of Prof. Gilbert R Thompson

2 Food and Drug Administration Criteria Required for Commencement of LDL Apheresis (1996) Patient characteristic LDL cholesterol (mg/dl) Homozygous FH 500 Heterozygous FH and failure of medical therapy Heterozygous FH with documented coronary disease and failure of medical therapy *FH=familial hypercholesterolemia LDL=low-density lipoprotein

3 Criteri di ammissione al trattamento di LDL-aferesi previsti dal Ministero della Sanità Tedesco Caratteristiche del paziente Ipercolesterolemia familiare omozigote da difetto recettoriale con LDL > 500 mg/dl Ipercolesterolemia grave con CHD documentata con target LDL< 130 mg/dl non raggiunto, nonostante massima terapia farmacologica e dietetica di 3 mesi Ipercolesterolemia grave con progressiva CHD documentata con Lp(a) > 60 mg/dl, anche se LDL < 130 mg/dl Linee guida approvate dalla Società Tedesca di Cardiologia

4 Extention of for RI of lipid apheresis in Germany valid from June 19th 2008 Isolated elevated Lp(a) level to > 60 mg/dl and normal LDL-cholesterol and simultaneously progressive cardiovascular disease documented by clinical and imaging techiques

5 Normal level of LDL-c not defined (probably according to target level of risk group acc. to EAS guidelines) First step is always first to get LdL-c on normal (targeted) level Cardiovascul. Disease: coronary heart disease, PAOD, cerebro-vascular disease

6 LDL-apheresis: I Italian Consensus Conference Guidelines (Ostuni 1990 Roma 1992) Homozygous Familial Hypercholesterolaemia (or double heterozygous) Heterozygous Familial Hypercholesterolaemia and other primary hypercholesterolaemia showing at least two of the following criteria: - lack of response to multiple dietary and pharmacological treatment - presence of severe atheromasia (symptomatic or asymptomatic, including preexisting Acute Myocardial Infarction) - coronary angioplasty, A-C by-pass (whenever pharmacological therapy does not guarantee the occurrence of restenosis) - heart transplant Claudia Stefanutti

7 GALLARATE MILANO TRIESTE FORLÌ REGGIO EMILIA PISTOIA PRATO L AQUILA VITERBO BARI SASSARI OZIERI ROMA Coordinating centre NUORO CAGLIARI PALERMO Italian Multicenter Study on LDL-apheresis Working Group (# 23 Centers)

8 IMSLDLa-WG centers not participating at 2009 survey, and Non- IMSLDLa-WP centres: sites, type of Unit (Specialty), patients per center, and devices used plus patients treated per device IMSLDLa-WG Center * Specialty # patients Device (# patients treated) Cagliari IM 24 HELP (13); Kaneka (6); DALI (5) Sassari 1 AR 22 Kaneka (14); HELP (4); DALI (4) Bari N 7 HELP (7) Total 53 Non- IMSLDLa-WG Center Matera IMSLDLa-WG: ITM 1 # 157 HELP (1) Catanzaro IM 3 HELP (3) Siena IM 2 HELP (2) Pisa CP (CNR) 28 Kaneka (18) HELP (5) Kaneka or Not belonging: # 54 HELP (5) Bologna (S.Orsola) ITM 7 DALI (4) HELP (3) Bologna (Malpighi) N 1 HELP (1) Orbassano ITM 3 Kaneka (2) HELP (1) Legnago N 2 HELP (2) Firenze Total patients under ITM treatment 2 in Italy: Kaneka # 211 (2) Genova ITM 2 DALI (2) Pietra Ligure ITM 1 DALI (1) Torino ITM 1 DALI (1) Novara ITM 1 DALI (1) Vicenza ITM 3 DALI (3) Total 57 *: Not participating at 2009 survey; : Source: Medical DeviceCompanies IM: Internal Medicine AR: Anesthesiology and Resuscitation N: Nephrology ITM: Immunohematology and Transfusion Medicine CP: Clinical Physiology (CNR: Consiglio Nazionale delle Ricerche; National Research Council)

9 Pediatric LDL-apheresis Refractoriness to diet and combined cholesterol-lowering drugs (at reasonably high doses) must be proven; diagnosis and complete cardiovascular examination (including catetherization) must be done; Begin LDLa between 6 and 7 years of age (or before); The delay in beginning LDLa (8-9 years) leads to the onset and progression of the aortic valvular disease; Treatment with LDLa imposes the reaching of therapeutic target (LDLC < 70mg/dL - ATP III) in children of high cardiovascular risk; Collateral effects of pediatric LDLa are rare if the procedure is carried out by a team of experts. The nd Italian Consensus Conference on LDL-apheresis Guidelines and recommendations

Regione Provincia Distretto Abruzzo Chieti DISTRETTO 009 Abruzzo Chieti DISTRETTO 010 Abruzzo Chieti DISTRETTO 011 Abruzzo Chieti DISTRETTO 015

Regione Provincia Distretto Abruzzo Chieti DISTRETTO 009 Abruzzo Chieti DISTRETTO 010 Abruzzo Chieti DISTRETTO 011 Abruzzo Chieti DISTRETTO 015 Regione Provincia Distretto Abruzzo Chieti DISTRETTO 009 Abruzzo Chieti DISTRETTO 010 Abruzzo Chieti DISTRETTO 011 Abruzzo Chieti DISTRETTO 015 Chieti Conteggio 4 Abruzzo L'Aquila DISTRETTO 001 Abruzzo

More information

IR Conference Call on PCSK9

IR Conference Call on PCSK9 IR Conference Call on PCSK9 SAR236553/REGN727 PCSK9 Antibody for Hypercholesterolemia Phase 3 ODYSSEY Program Underway November 5, 2012 1 Safe Harbor Statement This presentation contains forward-looking

More information

Recommendations for reporting of harmonised, non-fasting lipid cut-offs. David Sullivan and Graham Jones 12 Sept 2016

Recommendations for reporting of harmonised, non-fasting lipid cut-offs. David Sullivan and Graham Jones 12 Sept 2016 Recommendations for reporting of harmonised, non-fasting lipid cut-offs David Sullivan and Graham Jones 12 Sept 2016 Lipid Testing The Questions: Harmonised Reporting? (Y/N) What tests / calculations to

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and type 1 diabetes mellitus History: A 15-year-old girl is seen in the endocrinology clinic for a routine follow-up visit for type 1 diabetes. She was diagnosed with diabetes at 12 years

More information

Diabetes and cardiovascular risk: MIND.IT Study

Diabetes and cardiovascular risk: MIND.IT Study Diabetes and cardiovascular risk: MIND.IT Study The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy Prof. Ivana Zavaroni Dipartimento di Medicina

More information

Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia

Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia The Cardiac Society of Australia and New Zealand Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia This guideline was originally developed by David Sullivan, Gerard Watts, Ian

More information

South African Cholesterol Guidelines Compared

South African Cholesterol Guidelines Compared South African Cholesterol Guidelines Compared Jacqueline van Schoor, Amayeza Info Centre While infectious diseases are currently the leading cause of death in South Africa, cardiovascular disease (CVD)

More information

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015 Pre- and Post- Event Questionnaires The information on these slides is intended for educational purposes only.

More information

Zelené stezky - Greenways

Zelené stezky - Greenways Greenways in Europe Greenways, Zelené stezky, Zielone szlaki, Zöld Utak, Drumuri Verzi, Zelene staze, Зелёные тропы, Зелёные маршруты, Зелени кoридори, Grüne Hauptwege Prešov, March 6, 2009 Daniel Mourek,

More information

Prof. Elisabetta Cerbai University of Florence, Vice-Chancellor for Research Sapienza University of Rome, NVA Coordinator

Prof. Elisabetta Cerbai University of Florence, Vice-Chancellor for Research Sapienza University of Rome, NVA Coordinator Prof. Elisabetta Cerbai University of Florence, Vice-Chancellor for Research Sapienza University of Rome, NVA Coordinator Rome, October 14, 2014 1.Strategic Planning 2.From planning to facts 3.Evaluation:

More information

Miur-Contingente-Organici-Nomine-Docenti-201415.xlsx ] Titolari al 23.07.2014 Disponibil ità

Miur-Contingente-Organici-Nomine-Docenti-201415.xlsx ] Titolari al 23.07.2014 Disponibil ità Ordine scuola Provincia Posti o.d. 2014/15 Titolari al 23.07.2014 Disponibil ità Esubero contingente nazionale per nomine Infanzia Normale 81.601 77.582 4.019 2341 Primaria Normale 197.992 191.829 6.226

More information

Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Measuring the Effects of the 2008-09 Crisis on the Competitiveness of Italian Provinces

Measuring the Effects of the 2008-09 Crisis on the Competitiveness of Italian Provinces Measuring the Effects of the 2008-09 Crisis on the Competitiveness of Italian Provinces DICEA - Department of Civil, Architectural and Environmental Engineering Did the various territories react in the

More information

MIGHTY MEDIC. June 5 6, Updating on Apheresis and Atherosclerosis Research. Rome, Interdisciplinary Educational Forum

MIGHTY MEDIC. June 5 6, Updating on Apheresis and Atherosclerosis Research. Rome, Interdisciplinary Educational Forum 10 LIPID CLUB and Therapeutic Apheresis 2015 MIGHTY MEDIC Rome, June 5 6, 2015 / Interdisciplinary Educational Forum Updating on Apheresis and Atherosclerosis Research 10 LIPID CLUB and Therapeutic Apheresis

More information

Table 1: ZTL areas square meter of ZTL per inhabitants (reference year 2005)

Table 1: ZTL areas square meter of ZTL per inhabitants (reference year 2005) Title of the measure: ITA10 - Car-Restricted Areas Planning in Major Towns Z.T.L. ( Zone a Traffico Limitato) General description a. The Z.T.L. structure Since the end of the eighties, many Italian cities

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and obesity History: A 13-year-old girl is seen for a routine clinic follow-up visit. She has been previously healthy, but her growth curve shows increasing body mass index (BMI) percentiles

More information

Coronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines

Coronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new

More information

Cardiovascular Disease

Cardiovascular Disease Cardiovascular Disease Genetics in Primary Care: A Faculty Development Initiative A resident asks... Why should a primary care doctor want to know about genetics and cardiovascular (CV) disease? Key Points:

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia

An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates

More information

ITALY IN THE CREATIVE AGE

ITALY IN THE CREATIVE AGE CREATIVITYGROUPEUROPE presents ITALY IN THE CREATIVE AGE Irene Tinagli Richard Florida English summary June 0 Copyright c 0 Creativity Group Europe Italy in the Creative Age is part of the research project

More information

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Journal of Clinical Lipidology (2011) 5, 133 140 Executive Summary Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National

More information

Monitoring and evaluating the Italian programme for urban sustainable mobility

Monitoring and evaluating the Italian programme for urban sustainable mobility Monitoring and evaluating the Italian programme for urban sustainable mobility Maurizio Tomassini ISIS Istituto di Studi per l Integrazione dei Sistemi 1 Foreword The project has been developed jointly

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and type 2 diabetes mellitus History: A 17-year-old Hispanic female patient is seen for a routine clinic follow-up visit. She was diagnosed with type 2 diabetes 6 months ago. Her hemoglobin

More information

LOWERS FAST C O KEEPS LOW O C O. Benecol provides fast results and. dietary way to lower cholesterol

LOWERS FAST C O KEEPS LOW O C O. Benecol provides fast results and. dietary way to lower cholesterol C O O LOWERS FAST O C O KEEPS LOW Benecol provides fast results and keeps Benecol cholesterol - Effective at lower and level, easy naturally dietary way to lower cholesterol Dear Reader and Healthcare

More information

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events II European Action on Secondary and Primary Prevention through Intervention to Reduce Events Euro Heart Survey Programme European Society of Cardiology-ESC 1 2 Priorities of Coronary Heart Disease Prevention

More information

Prevention of Cardiovascular Disease in Children with Diabetes

Prevention of Cardiovascular Disease in Children with Diabetes Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus

More information

Eventuale spazio per nome struttura o altro. Pharmacy education. The Italian academic viewpoint

Eventuale spazio per nome struttura o altro. Pharmacy education. The Italian academic viewpoint Eventuale spazio per nome struttura o altro Pharmacy education. The Italian academic viewpoint Faculty of Pharmacy Total number of Pharmacy higher education institutes in Italy 1. Faculty of Pharmacy,

More information

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES Test Code Test Name CPT CHOL Cholesterol, Serum 82465 HDL HDL, (High Density Lipoprotein) 83718 TRIG Triglycerides, Serum 84478 FTRIG Triglycerides (Fluid) 84478 LIPID Lipid Panel 80061 LDL LDL (Low Density

More information

F ORMATO EUROPEO PER IL CURRICULUM VITAE

F ORMATO EUROPEO PER IL CURRICULUM VITAE F ORMATO EUROPEO PER IL CURRICULUM VITAE INFORMAZIONI PERSONALI Name and surname Address Phone E-mai Date and place of birth Diploma Graduation Francesca Mallamaci Reggio Calabria Via Torrione n. 42 (CAP

More information

NUTS! The Story of My Life. Prof. Joan Sabaté Department of Nutrition Loma Linda University

NUTS! The Story of My Life. Prof. Joan Sabaté Department of Nutrition Loma Linda University NUTS! The Story of My Life Prof. Joan Sabaté Department of Nutrition Loma Linda University Dr. Joan Sabate Chair, Nutrition, School of Public Health, Loma Linda University CA From Spain, Dr. Sabaté is

More information

ITALIAN NATIONAL BLOOD CENTRE REGULATION OF CORD BLOOD BANKING: GLOBAL IMPLICATIONS

ITALIAN NATIONAL BLOOD CENTRE REGULATION OF CORD BLOOD BANKING: GLOBAL IMPLICATIONS ITALIAN NATIONAL BLOOD CENTRE REGULATION OF CORD BLOOD BANKING: GLOBAL IMPLICATIONS Paolo Rebulla European Directives National Laws In the case of blood and blood components & tissues and cells European

More information

La facilitazione alla PCI con statine

La facilitazione alla PCI con statine La facilitazione alla PCI con statine Bertinoro, 16 aprile 2010 Aldo Miola, M.D., Ph.D. Medical Manager Primary Care Pfizer Italy 1 Are statins beneficial in patients undergoing PCI? 2 3 Statin therapy

More information

Mar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations

Mar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE

More information

Cholesterol - New Guidelines and Treatment Protocols

Cholesterol - New Guidelines and Treatment Protocols Cholesterol - New Guidelines and Treatment Protocols By: James L. Holly, MD The New Year brings new opportunities to improve our health. Many of us receive gifts which we can't use because there's too

More information

CURRICULUM VITÆ. Prof. FRANCESCO DONATELLI

CURRICULUM VITÆ. Prof. FRANCESCO DONATELLI CURRICULUM VITÆ Prof. FRANCESCO DONATELLI CHAIR OF CARDIOTHORACIC SURGERY UNIVERSITA DEGLI STUDI DI MILANO MILAN - ITALY - HEAD OF DEPARTMENT CARDIOVASCULAR SURGERY ISTITUTO CLINICO SANT AMBROGIO GRUPPO

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes

Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Non-HDL Cholesterol: When and How to Treat

Non-HDL Cholesterol: When and How to Treat September 01, 2008 By Edward J. Shahady, MD [1] Over the past 4 decades, our understanding of the role of elevated cholesterol in cardiovascular disease (CVD) has undergone radical change. During that

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

New Cholesterol Treatment Guidelines. Charles F. Dahl, MD, FACC Cardiologist and Lipidologist, Central Utah Clinic

New Cholesterol Treatment Guidelines. Charles F. Dahl, MD, FACC Cardiologist and Lipidologist, Central Utah Clinic New Cholesterol Treatment Guidelines Charles F. Dahl, MD, FACC Cardiologist and Lipidologist, Central Utah Clinic Objectives: List the 4 treatment groups under the new guidelines Identify how to calculate

More information

Clinical Trials for PCSK9

Clinical Trials for PCSK9 2014 NLA Scientific Sessions, Orlando, FL Clinical Trials for PCSK9 James M. McKenney, PharmD President and CEO, National Clinical Research, Inc. Professor Emeritus, Virginia Commonwealth University Richmond,

More information

THE ECONOMIC DYNAMISM OF ITALY S PROVINCES

THE ECONOMIC DYNAMISM OF ITALY S PROVINCES Aspen Institute Italia National Interest Project August 2009 THE ECONOMIC DYNAMISM OF ITALY S PROVINCES MEASURING LOCAL INDUSTRIAL EXCELLENCE The analysis was conducted at provincial level. The weighted

More information

High Cholesterol (Hyperlipidemia)

High Cholesterol (Hyperlipidemia) High Cholesterol (Hyperlipidemia) My cholesterol medication is: The directions are: In recent years, powerful new drugs have been developed to reduce cholesterol in your blood, thereby reducing your risk

More information

Digital performance of Italy

Digital performance of Italy Digital performance of Italy Broadband markets At the end of 2013, fixed broadband covered 99% of homes in Italy (97% in the EU). In rural areas, fixed broadband covered 88% of homes. At the same time,

More information

Breaking News in Malattie del Ricambio

Breaking News in Malattie del Ricambio Paolo Cavallo Perin Dipartimento di Scienze Mediche Università di Torino Breaking News in Malattie del Ricambio Modena, 1 ottobre 2015 Breaking News Malattie del Ricambio 1. Terapia dislipidemie: evolocumab

More information

Endorsement Summary: Cardiovascular Measures

Endorsement Summary: Cardiovascular Measures January 2012 Purpose of the Project The human and financial costs of cardiovascular disease are enormous. Heart disease is the leading cause of death for men and women in the United States and was estimated

More information

PRALUENT (alirocumab) ICD-10 Pocket Guide

PRALUENT (alirocumab) ICD-10 Pocket Guide PRALUENT (alirocumab) ICD-10 Pocket Guide Your guide to ICD-10 coding for clinical atherosclerotic cardiovascular disease (ASCVD) INDICATION AND USAGE PRALUENT (alirocumab) is a PCSK9 (Proprotein Convertase

More information

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

my Complete Cholesterol Profile and Action Plan

my Complete Cholesterol Profile and Action Plan my Complete Cholesterol Profile and Action Plan Your healthcare provider, along with this brochure, can help you better understand your Complete Cholesterol Profile, which may help you improve your cholesterol

More information

AHA/ASA Guidelines on Prevention of Recurrent Stroke

AHA/ASA Guidelines on Prevention of Recurrent Stroke AHA/ASA Guidelines on Prevention of Recurrent Stroke MARA LAMBERT Guideline source: American Heart Association/American Stroke Association Evidence rating system used? Yes Literature search described?

More information

An important first step in identifying those at risk for Cardiovascular disease The Accutrend Plus system: from the makers of the ACCU-CHEK and

An important first step in identifying those at risk for Cardiovascular disease The Accutrend Plus system: from the makers of the ACCU-CHEK and An important first step in identifying those at risk for Cardiovascular disease The Accutrend Plus system: from the makers of the ACCU-CHEK and CoaguChek systems Cardiovascular disease: the #1 killer in

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

First step: determine the goal for dyslipidemia treatment (primary prevention vs. secondary prevention)

First step: determine the goal for dyslipidemia treatment (primary prevention vs. secondary prevention) The American college of cardiology (ACC) and American Heart Association (AHA) in combination with National Heart, Lung and blood institute (NHLBI) have released 4 new guidelines. At the invitation of the

More information

Diagnosis Code Crosswalk : ICD 9 CM to ICD 10 CM Coronary and Peripheral Vascular

Diagnosis Code Crosswalk : ICD 9 CM to ICD 10 CM Coronary and Peripheral Vascular Diagnosis Code Crosswalk : to Coronary and Peripheral Vascular 411.1 Intermediate coronary syndrome (unstable angina) I20.0 Unstable angina 412 Old myocardial infarction I25.2 Old myocardial infarction

More information

Who we are. We are 17,000 men and women who form a cooperative banking group with 1,800 branches.

Who we are. We are 17,000 men and women who form a cooperative banking group with 1,800 branches. Who we are We are 17,000 men and women who form a cooperative banking group with 1,800 branches. Over the past 150 years, we have become part of the history of the households and businesses in our local

More information

Expert Commentary. A response to the recent JAMA meta analysis on omega 3 supplementation and cardiovascular events

Expert Commentary. A response to the recent JAMA meta analysis on omega 3 supplementation and cardiovascular events Expert Commentary A response to the recent JAMA meta analysis on omega 3 supplementation and cardiovascular events Dr. Bruce J. Holub, Ph.D., Professor Emeritus, University of Guelph Expert Commentary:

More information

Guidelines for the management of dyslipidaemia in patients with diabetes mellitus

Guidelines for the management of dyslipidaemia in patients with diabetes mellitus Guidelines for the management of dyslipidaemia in patients with diabetes mellitus Quick reference guide More than 60% of type 2 diabetic subjects in the Eastern Mediterranean Region have some degree of

More information

Who we are. We are 17,000 men and women who form a cooperative banking group with 1,800 branches.

Who we are. We are 17,000 men and women who form a cooperative banking group with 1,800 branches. Who we are We are 17,000 men and women who form a cooperative banking group with 1,800 branches. Over the past 150 years, we have become part of the history of the households and businesses in our local

More information

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts.

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts. LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts Introduction While both small and large LDL particles may be atherogenic,

More information

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause

More information

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol!

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol! Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities

More information

Managing Dyslipidemias in Patients With Chronic Kidney Disease

Managing Dyslipidemias in Patients With Chronic Kidney Disease Managing Dyslipidemias in Patients With Chronic Kidney Disease Causes of Death Among Period Prevalent Patients, 1997-1999, Treated with Hemodialysis, Peritoneal Dialysis or Kidney Transplantation Abbreviations:

More information

Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)

Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves

More information

Central Office N/A N/A

Central Office N/A N/A LCD ID Number L32688 LCD Title Cardiac Rehabilitation and Intensive Cardiac Rehabilitation Contractor s Determination Number L32688 AMA CPT/ADA CDT Copyright Statement CPT only copyright 2002-2011 American

More information

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE 1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Guideline title SCOPE Hypertension: clinical management of primary hypertension in adults 1.1 Short title Hypertension (partial update) 2 The remit

More information

SINCE MORE THAN FIFTY YEARS IN THE DIRECT CURRENT ALL OVER THE WORLD

SINCE MORE THAN FIFTY YEARS IN THE DIRECT CURRENT ALL OVER THE WORLD SINCE MORE THAN FIFTY YEARS IN THE DIRECT CURRENT ALL OVER THE WORLD Total Number of Rectifiers Manufactured : N 1063 INDUSTRY APPLICATIONS TRACTION APPLICATIONS TOTAL Country Projects N Rectifiers N Projects

More information

New-Onset Diabetes after Transplantation

New-Onset Diabetes after Transplantation New-Onset Diabetes after Transplantation Dr Mahmoud Darouich Ministry of Health - Damascus The tenth conference of syrian society of nephrology and transplantation Mashta-Alhelou 6-8/11/2008 Cause of Death

More information

Understanding and Managing Your. Triglycerides

Understanding and Managing Your. Triglycerides Understanding and Managing Your Triglycerides What are Triglycerides? There are several types are one of several types of fat in your body, and triglycerides are the most common. Along with LDL ( bad )

More information

NCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

NCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,

More information

European Cholesterol Guidelines Report. Policy Analysis Centre. Tony Hockley & Marin Gemmill

European Cholesterol Guidelines Report. Policy Analysis Centre. Tony Hockley & Marin Gemmill Policy Analysis Centre European Cholesterol Guidelines Report Tony Hockley & Marin Gemmill Foreword by Professor Elias Mossialos, Director, London School of Economics & Political Science (LSE) Contents:

More information

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Stent for Life Initiative How can we improve system delay and patients delay in STEMI Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration

More information

Non-HDL Cholesterol: When and How to Treat

Non-HDL Cholesterol: When and How to Treat EDWARD J. SHAHADY, MD University of Miami Non-HDL Cholesterol: Dr Shahady is clinical professor of family medicine at the University of Miami in Florida; an associate faculty member in the residency program

More information

A CLOSER L OOK AT A JOINT PROJECT BETWEEN T HE A MERICAN H EART A SSOCIATION AND T HE N ATIONAL P HARMACEUTICAL C OUNCIL

A CLOSER L OOK AT A JOINT PROJECT BETWEEN T HE A MERICAN H EART A SSOCIATION AND T HE N ATIONAL P HARMACEUTICAL C OUNCIL A CLOSER L OOK AT Americans pay $53.4 billion each year for medical care of heart disease. An additional $47.4 billion is lost due to premature death and lower productivity. A JOINT PROJECT BETWEEN T HE

More information

Chin J Hypertension, Feb 2007, Vol. 15 No 2

Chin J Hypertension, Feb 2007, Vol. 15 No 2 132 2007 2 15 2 Chin J Hypertension, Feb 2007, Vol. 15 No 2 1, 2, 2 52,(LDL2C) ( n = 17) ( n = 35), ( ) (40 mg/ d) 6 ( PWV) (ABI) 6, LDL2C [ (211 013) vs (116 013), (314 018) vs (213 015) mmol/ L, P

More information

Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions

Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions The case of Milan Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions 35 34.08 Milan Province 33 31 Highest GDP

More information

Education. Panel. Triglycerides & HDL-C

Education. Panel. Triglycerides & HDL-C Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified

More information

Statins: Can there be too much of a good thing?

Statins: Can there be too much of a good thing? Statins: Can there be too much of a good thing? Spoiler alert No Oh Contraire Haaaaiiiiiiile No! Frequently under prescribing statin therapy! Typical Case 68 YO Smoker ACS Multiple prior PCI s Multiple

More information

Emerging Options for Elevated LDL Cholesterol: Focus on PCSK9 Inhibitors

Emerging Options for Elevated LDL Cholesterol: Focus on PCSK9 Inhibitors Emerging Options for Elevated LDL Cholesterol: Focus on PCSK9 Inhibitors Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular Programs Brigham and Women

More information

American Fidelity Assurance Company s. AF Critical Choice. Limited Benefit Critical Illness Insurance. Financial Protection is a Choice

American Fidelity Assurance Company s. AF Critical Choice. Limited Benefit Critical Illness Insurance. Financial Protection is a Choice American Fidelity Assurance Company s AF Critical Choice Limited Benefit Critical Illness Insurance Financial Protection is a Choice Critical Illness Surviving a critical illness can come at a high price.

More information

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology

More information

Rx Updates New Guidelines, New Medications What You Need to Know

Rx Updates New Guidelines, New Medications What You Need to Know Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact

More information

HOT TOPICS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

HOT TOPICS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE 9 t h S u m m e r S c h o o l o f t h e H e l l e n i c A t h e r o s c l e r o s i s S o c i e t y HOT TOPICS IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE June 30 th July 2 nd 2016, Royal

More information

Your Guide to Express Critical Illness Insurance Definitions

Your Guide to Express Critical Illness Insurance Definitions Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses

More information

RECORDATI: VERY GOOD FIRST NINE MONTHS 2011 RESULTS. SALES +5.8%. NET INCOME +5.8%. INTERIM DIVIDEND DISTRIBUTION POLICY APPROVED.

RECORDATI: VERY GOOD FIRST NINE MONTHS 2011 RESULTS. SALES +5.8%. NET INCOME +5.8%. INTERIM DIVIDEND DISTRIBUTION POLICY APPROVED. RECORDATI: VERY GOOD FIRST NINE MONTHS RESULTS. SALES +5.8%. NET INCOME +5.8%. INTERIM DIVIDEND DISTRIBUTION POLICY APPROVED. Consolidated revenue 580.6 million, + 5.8%. Operating income 128.9 million,

More information

Pharmaceutical Company Driven Disease Management in Medicare Part D: Opportunities and Threats

Pharmaceutical Company Driven Disease Management in Medicare Part D: Opportunities and Threats Pharmaceutical Company Driven Disease Management in Medicare Part D: Opportunities and Threats Barry Patel, Pharm.D. President and Co-Founder Total Therapeutic Management, Inc. Objectives Discuss the opportunities

More information

NCD for Lipids Testing

NCD for Lipids Testing Applicable CPT Code(s): NCD for Lipids Testing 80061 Lipid panel 82465 Cholesterol, serum or whole blood, total 83700 Lipoprotein, blood; electrophoretic separation and quantitation 83701 Lipoprotein blood;

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

HEDIS CY2012 New Measures

HEDIS CY2012 New Measures HEDIS CY2012 New Measures TECHNICAL CONSIDERATIONS FOR NEW MEASURES The NCQA Committee on Performance Measurement (CPM) approved five new measures for HEDIS 2013 (CY2012). These measures provide feasible

More information

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism Major Classes of Drugs Available Affecting Lipoprotein Metabolism HMG CoA reductase inhibitors lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin cholestyramine, colestipol, colesevelam crystalline,

More information

SPACI & EGEE LCG on IA64

SPACI & EGEE LCG on IA64 SPACI & EGEE LCG on IA64 Dr. Sandro Fiore, University of Lecce and SPACI December 13 th 2005 www.eu-egee.org Outline EGEE Production Grid SPACI Activity Status of the LCG on IA64 SPACI & EGEE Farm Configuration

More information

Agenzia Nazionale LLP ERASMUS Intensive Programme A.A. 2012/2013 ATTRIBUZIONI

Agenzia Nazionale LLP ERASMUS Intensive Programme A.A. 2012/2013 ATTRIBUZIONI N. ID Code Erasmus Denominazione Istituto Numero Candidatura Numero Accordo Nuovo Rinnovo Titolo dell' 1 I VENEZIA02 Università Iuav di Venezia 12_MB_IP_00009 2012-1-IT2-ERA10-38826 x Villard European

More information

Cholesterol Congestion

Cholesterol Congestion Cholesterol Congestion How your blood cholesterol traffic is measured The odds of getting cardiovascular disease are very high; it is the main cause of death in the US and more than one in four Americans

More information

Is Telemedicine an useful tool for Atrial Fibrillation?

Is Telemedicine an useful tool for Atrial Fibrillation? THIRD INTERNATIONAL TELEMEDICINE WORKSHOP by SIT at Exposanità 2008: Is Telemedicine an useful tool for Atrial Fibrillation? Data from Italy and China PhD Jun Ma Tongji University in Shanghai, P.R.C. Bologna,

More information

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011

More information

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease

More information